Distribution of ILD in anti-Ro52 positive patients with various underlying diseases
| Total | Ro52+Ro60− | Ro52+Ro60+ | OR | 95% Cl | P value | |
| CTD* | 490 (37.1%) | 352 (55.4%) | 138 (20.1%) | 4.94 | 3.88 to 6.31 | <0.0001 |
| IIM ‡ | 123 (85.4%) | 99 (88.4%) | 24 (75.0%) | 2.54 | 0.93 to 6.77 | >0.05 |
| DM | 84 (87.5%) | 66 (86.8%) | 18 (90.0%) | 0.73 | 0.15 to 3.22 | >0.05 |
| PM | 18 (66.7%) | 15 (83.3%) | 3 (33.3%) | 10.00 | 1.42 to 48.96 | <0.01 |
| ASS | 21 (100.0%) | 18 (100.0%) | 3 (100.0%) | |||
| pSS | 236 (38.2%) | 157 (57.3%) | 79 (23.0%) | 4.50 | 3.17 to 6.31 | <0.0001 |
| SLE | 18 (6.5%) | 4 (7.4%) | 14 (6.3%) | 1.18 | 0.41 to 3.64 | >0.05 |
| RA | 36 (43.4%) | 29 (60.4%) | 7 (20.0%) | 6.11 | 2.12 to 15.16 | <0.001 |
| SSc | 15 (51.7%) | 11 (57.9%) | 4 (40.0%) | 2.06 | 0.44 to 8.04 | >0.05 |
| UCTD | 49 (64.5%) | 44 (69.8%) | 5 (38.5%) | 3.71 | 1.16 to 11.61 | <0.05 |
| MCTD/overlap syndrome | 7 (46.7%) | 3 (30.0%) | 4 (80.0%) | 0.11 | 0.01 to 1.50 | >0.05 |
| Vasculitis | 6 (35.3%) | 5 (38.5%) | 1 (25.0%) | 1.88 | 0.21 to 28.67 | >0.05 |
| Non-CTD† | 72 (10.9%) | 68 (12.2%) | 4 (3.9%) | 3.41 | 1.25 to 8.95 | <0.05 |
Data were shown as number (percentage of ILD patients for each disease). Ro52+Ro60–: anti-Ro52 positive and anti-Ro60 negative, Ro52+Ro60+: both anti-Ro52 and anti-Ro60 positive.
*Diagnosis of CTDs was in accordance with the international criteria for classification.
†Patients without a definite CTD during the hospitalisation, of which tumour, infection, ILD and chronic kidney disease were the most common disease types.
‡including DM, PM and ASS.
ASS, anti-synthetase syndrome; CTD, connective tissue disease; DM, dermatomyositis; IIM, idiopathic inflammatory myopathy; MCTD, mixed connective tissue disease; PM, polymyositis; pSS, primary Sjögren's syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease.